106 related articles for article (PubMed ID: 26373261)
1. HepG2 Cell Resistance against Camptothecin from a Lysosomal Drug Delivery.
Lee H; Uhm S; Shin JW; Jeon HM; Dongbang S; Jung HS; Na YC; Kang C; Kim JS
Chem Asian J; 2015 Dec; 10(12):2695-700. PubMed ID: 26373261
[TBL] [Abstract][Full Text] [Related]
2. Core-crosslinked nanomicelles based on crosslinkable prodrug and surfactants for reduction responsive delivery of camptothecin and improved anticancer efficacy.
He W; Du Y; Zhou W; Wang T; Li M; Li X
Eur J Pharm Sci; 2020 Jul; 150():105340. PubMed ID: 32371069
[TBL] [Abstract][Full Text] [Related]
3. The self-assembly of anticancer camptothecin-dipeptide nanotubes: a minimalistic and high drug loading approach to increased efficacy.
Kim SH; Kaplan JA; Sun Y; Shieh A; Sun HL; Croce CM; Grinstaff MW; Parquette JR
Chemistry; 2015 Jan; 21(1):101-5. PubMed ID: 25384556
[TBL] [Abstract][Full Text] [Related]
4. A small-sized graphene oxide supramolecular assembly for targeted delivery of camptothecin.
Zhang YM; Cao Y; Yang Y; Chen JT; Liu Y
Chem Commun (Camb); 2014 Nov; 50(86):13066-9. PubMed ID: 25222700
[TBL] [Abstract][Full Text] [Related]
5. Self-assembling nanomicelles of a novel camptothecin prodrug engineered with a redox-responsive release mechanism.
Li XQ; Wen HY; Dong HQ; Xue WM; Pauletti GM; Cai XJ; Xia WJ; Shi D; Li YY
Chem Commun (Camb); 2011 Aug; 47(30):8647-9. PubMed ID: 21725532
[TBL] [Abstract][Full Text] [Related]
6. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance.
Liu M; Chen D; Mukerabigwi JF; Chen S; Zhang Y; Lei S; Luo S; Wen Z; Cao Y; Huang X; He H
J Drug Target; 2016; 24(5):433-40. PubMed ID: 26422582
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of small interfering RNA using a camptothecin prodrug as the carrier.
Tang Q; Cao B; Cheng G
Chem Commun (Camb); 2014 Feb; 50(11):1323-5. PubMed ID: 24343195
[TBL] [Abstract][Full Text] [Related]
8. Biocleavable graphene oxide based-nanohybrids synthesized via ATRP for gene/drug delivery.
Yang X; Zhao N; Xu FJ
Nanoscale; 2014 Jun; 6(11):6141-50. PubMed ID: 24789325
[TBL] [Abstract][Full Text] [Related]
9. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.
Lundberg BB
Anticancer Drug Des; 1998 Jul; 13(5):453-61. PubMed ID: 9702210
[TBL] [Abstract][Full Text] [Related]
10. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
11. Shape design of high drug payload nanoparticles for more effective cancer therapy.
Li W; Zhang X; Hao X; Jie J; Tian B; Zhang X
Chem Commun (Camb); 2013 Dec; 49(93):10989-91. PubMed ID: 24136236
[TBL] [Abstract][Full Text] [Related]
12. Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug.
Lee MH; Kim JY; Han JH; Bhuniya S; Sessler JL; Kang C; Kim JS
J Am Chem Soc; 2012 Aug; 134(30):12668-74. PubMed ID: 22642558
[TBL] [Abstract][Full Text] [Related]
13. A theranostic prodrug based on FRET for real-time drug release monitoring in response to biothiols.
Hu Y; Zeng F
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():77-85. PubMed ID: 28024642
[TBL] [Abstract][Full Text] [Related]
14. Design and evaluation of glutathione responsive glycosylated camptothecin nanosupramolecular prodrug.
Li W; Chen Z; Liu X; Lian M; Peng H; Zhang C
Drug Deliv; 2021 Dec; 28(1):1903-1914. PubMed ID: 34519602
[TBL] [Abstract][Full Text] [Related]
15. Creation of pure nanodrugs and their anticancer properties.
Kasai H; Murakami T; Ikuta Y; Koseki Y; Baba K; Oikawa H; Nakanishi H; Okada M; Shoji M; Ueda M; Imahori H; Hashida M
Angew Chem Int Ed Engl; 2012 Oct; 51(41):10315-8. PubMed ID: 22969010
[No Abstract] [Full Text] [Related]
16. Probing a dipeptide-based supramolecular assembly as an efficient camptothecin delivering carrier for cancer therapy: computational simulations and experimental validations.
Sun M; Zhang X; Gao Z; Liu T; Luo C; Zhao Y; Liu Y; He Z; Wang J; Sun J
Nanoscale; 2019 Feb; 11(9):3864-3876. PubMed ID: 30758022
[TBL] [Abstract][Full Text] [Related]
17. Enhanced in vitro antitumor efficacy and strong anti-cell-migration activity of a hydroxycamptothecin-encapsulated magnetic nanovehicle.
Ding GB; Liu HY; Lv YY; Liu XF; Guo Y; Sun CK; Xu L
Chemistry; 2012 Oct; 18(44):14037-46. PubMed ID: 22996598
[TBL] [Abstract][Full Text] [Related]
18. Molecularly precise dendrimer-drug conjugates with tunable drug release for cancer therapy.
Zhou Z; Ma X; Murphy CJ; Jin E; Sun Q; Shen Y; Van Kirk EA; Murdoch WJ
Angew Chem Int Ed Engl; 2014 Oct; 53(41):10949-55. PubMed ID: 25155439
[TBL] [Abstract][Full Text] [Related]
19. Uniform iron oxide hollow spheres for high-performance delivery of insoluble anticancer drugs.
Zhu Y; Lei J; Tian Y
Dalton Trans; 2014 May; 43(19):7275-81. PubMed ID: 24691463
[TBL] [Abstract][Full Text] [Related]
20. Triggered drug release from superhydrophobic meshes using high-intensity focused ultrasound.
Yohe ST; Kopechek JA; Porter TM; Colson YL; Grinstaff MW
Adv Healthc Mater; 2013 Sep; 2(9):1204-8. PubMed ID: 23592698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
